Purpose: This is a Phase 2, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 180 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, and a 90-day follow-up period.
Arms and Assigned Interventions:
- Experimental: Tremelimumab
- Drug: Tremelimumab
- Tremelimumab is to be administered as an IV solution, followed by observation.
- Placebo Comparator: Placebo
- Drug: Placebo
- Placebo is to be administered as an IV solution, followed by observation.